15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Haemonetics Corporation, 6 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $62.00 to $99.00, a moderate spread. The average target of $81.11 sits 2% below the current $82.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.27 next quarter toward $5.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy667%
Hold333%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Haemonetics Corporation.
As of Jul, 6 of 9 firms rate HAE a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HAE EPS & revenue forecast
EPS · NEXT QUARTER
$1.27
Range $1.18 – $1.34 · 11 analysts · +0% YoY
Next period, 11 analysts expect Haemonetics Corporation to earn $1.27 a share (range $1.18 – $1.34), versus $1.27 a year earlier. Full-year consensus is $5.22, growing to $5.63 the year after.
REVENUE · NEXT QUARTER
$342.6M
Range $335.9M – $349.5M · 11 analysts · +5% YoY
Revenue is expected to reach $342.6M (range $335.9M – $349.5M), +4.7% year-over-year. Full-year consensus is $1.4B, rising to $1.5B next year.
Top analysts covering Haemonetics Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HAE.
#1
Mike Matson
Needham · Rank #204
Hold
No targeton HAE
Overall win rate
31%
+ Follow
#2
Michael Petusky
Barrington Research · Rank #322
Buy
$89.00+7.8% to target
Overall win rate
29%
+ Follow
#3
Anthony Petrone
Mizuho
Buy
$90.00+9.1% to target
Coverage
—
+ Follow
#4
MT
Marie Thibault
BTIG
Buy
$84.00+1.8% to target
Coverage
—
+ Follow
#5
Joanne Wuensch
Citigroup
Hold
$70.00-15.2% to target
Coverage
—
+ Follow
HAE stock forecast FAQ
What is HAE's average 12-month price target?+
The 8 analysts with a live target average $81.11 for Haemonetics Corporation over the next 12 months, ranging from a $99.00 high to a $62.00 low.
Is HAE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 6 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HAE?+
The Street-high target is $99.00 (Baird), and the Street-low is $62.00 (JP Morgan). The average of all 8 active targets is $81.11.
How many Wall Street analysts cover HAE?+
9 analysts have an active rating on Haemonetics Corporation, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering HAE?+
Among analysts who currently cover HAE, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #204). Their current call is Hold.
What is Haemonetics Corporation's projected EPS for next quarter?+
The consensus estimate is $1.27 per share (range $1.18 – $1.34) across 11 analysts. Full-year EPS is projected at $5.22, rising to $5.63 the following year.
How much revenue is Haemonetics Corporation expected to report next quarter?+
Consensus revenue is $342.6M (range $335.9M – $349.5M). Full-year revenue is projected at $1.4B, growing to $1.5B next year.
Have analysts been upgrading or downgrading HAE lately?+
As of Jul, 6 of 9 firms rate HAE a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HAE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
